Linaclotide: New mechanisms and new promise for treatment in constipation and irritable bowel syndrome

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 6, 2013, Pages 268-276

  Sood, Ruchit ^a   Ford, Alexander C ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Abdominal pain; Constipation; Diarrhoea; Irritable bowel syndrome; Linaclotide

Indexed keywords

BISACODYL; LINACLOTIDE; MACROGOL; PICOSULFATE SODIUM; PLACEBO; PLECANATIDE; PRUCALOPRIDE;

ABDOMINAL PAIN; BLOATING; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROPATHY; FECES ANALYSIS; HEADACHE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC);

EID: 84890221715     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313500110     Document Type: Article

References (35)

1. Andresen V. Camilleri M. Busciglio I. Grudell A. Burton D. Mckinzie S. et al. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133: 761–768.
2. Busby R. Bryant A. Bartolini W. Cordero E. Hannig G. Kessler M. et al. (2010). Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 15: 328–335.
3. Chang J. Locke G. III Mcnally M. Halder S. Schleck C. Zinsmeister A. et al. (2010) Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 105: 822–832.
4. Chey W. Lembo A. Lavins B. Shiff S. Kurtz C. Currie M. et al. (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107: 1702–1712.
5. Cinca R. Chera D. Gruss H. Halphen M. (2013) Randomised clinical trial: macrogol / PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation – a comparison in a controlled environment. Aliment Pharmacol Ther 37: 876–886.
6. Drossman D. Chey W. Johanson J. Fass R. Scott C. Panas R. et al. (2009) Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 29: 329–341.
7. Drossman D. Whitehead W. Toner B. Diamant N. Hu Y. Bangdiwala S. et al. (2000) What determines severity amongst patients with painful functional bowel disorders? Am J Gastroenterol 95: 974–980.
8. Eutamene H. Bradesi S. Larauche M. Theodorou V. Beaufrand C. Ohning G. et al. (2010) Guanylate cyclase-C mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 22: 312–e84.
9. Evans B. Clark W. Moore D. Whorwell P. (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev (4): CD003960.
10. FDA (2007) Public Health Advisory: tegaserod maleate (marketed as Zelnorm). Available at: http://www.fda.gov/cder/drug/advisory/tegaserod.htm (accessed 15 May 2013).
11. Ford A. Brandt L. Young C. Chey W. Foxx-Orenstein A. Moayyedi P. (2009 a) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 104: 1831–1843.
12. Ford A. Forman D. Bailey A. Axon A. Moayyedi P. (2012) Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 107: 912–921.
13. Ford A. Marwaha A. Lim A. Moayyedi P. (2010) Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 8: 401–409.
14. Ford A. Suares N. (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60: 209–218.
15. Ford A. Talley N. Schoenfeld P. Quigley E. Moayyedi P. (2009 b) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58: 367–378.
16. Ford A. Talley N. Spiegel B. Foxx-Orenstein A. Schiller L. Quigley E. et al. (2008) Effect of fibre, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. Br Med J 337: 1388–1392.
17. Johanson J. Morton D. Geene J. Ueno R. (2008) Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103: 170–177.
18. Johnston J. Kurtz C. Drossman D. Lembo A. Jeglinski B. MacDougall J. et al. (2009) Pilot study on the Effects of linaclotide in patients with chronic constipation. Am J Gastroenterol 104: 125–132.
19. Johnston J. Kurtz C. MacDougall J. Lavins B. Currie M. Fitch D. et al. (2010) Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome and constipation. Gastroenterology 139: 1877–1886.
20. Lembo A. Kurtz C. MacDougall J. Lavins B. Currie M. Fitch D. et al. (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138: 886–895.
21. Lembo A. Schneier H. Shiff S. Kurtz C. MacDougall J. Jia X. et al. (2011) Two randomized trials of linaclotide for chronic constipation. N Engl J Med 365: 527–536.
22. Longstreth G. Thompson W. Chey W. Houghton L. Mearin F. Spiller R. (2006) Functional bowel disorders. Gastroenterology 130: 1480–1491.
23. Lovell R. Ford A. (2012 a) Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol 107: 1793–1801.
24. Lovell R. Ford A. (2012 b) Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 107: 991–1000.
25. Lovell R. Ford A. (2012 c) Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712–721.
26. Maxion-Bergemann S. Thielecke F. Abel F. Bergemann R. (2006) Costs of irritable bowel syndrome in the UK and US. Pharmaco Economics 24: 21–37.
27. Moayyedi P. Ford A. Brandt L. Foxx-Orenstein A. Cremonini F. Talley N. et al. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325–332.
28. Peery A. Dellon E. Lund J. Crockett S. McGowan C. Bulsiewicz W. et al. (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143: 1179–1187.
29. Quigley E. Tack J. Chey W. Rao S. Fortea J. Falques M. et al. (2013) Randomised clinical trials: linaclotide phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 37: 49–61.
30. Rao S. Lembo A. Shiff S. Lavins B. Currie M. Jia X. et al. (2012) 12-Week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107: 1714–1724.
31. Shailubhai K. Barrow L. Talluto C. Comiskey S. Foss J. Feng R. et al. (2011) Plecanatide, a guanylate cyclase C agonist improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study. Am J Gastroenterol 106(Suppl. 2s): S502.
32. Suares N. Ford A. (2011 a) Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 33: 895–901.
33. Suares N. Ford A. (2011 b) Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 106: 1582–1591.
34. Wald A. Scarpignato C. Kamm M. Mueller-Lissner S. Helfrich I. Schuijt C. et al. (2007) The burden of chronic constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 26: 227–236.
35. Wong R. Palsson O. Turner M. Levy R. Feld A. von Korff M. et al. (2010) Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 105: 2228–2234.